204 related articles for article (PubMed ID: 25154405)
21. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
22. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
Candelaria M; Cetina L; Pérez-Cárdenas E; de la Cruz-Hernández E; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Chanona J; Arias D; Dueñas-González A
Eur J Gynaecol Oncol; 2010; 31(4):386-91. PubMed ID: 20882878
[TBL] [Abstract][Full Text] [Related]
24. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
Lin KT; Wang YW; Chen CT; Ho CM; Su WH; Jou YS
Clin Cancer Res; 2012 Sep; 18(17):4691-701. PubMed ID: 22811583
[TBL] [Abstract][Full Text] [Related]
25. Response to hydralazine-valproate in a patient with mycosis fungoides.
Dueñas-Gonzalez A; Vega MT; Martinez-Baños D; García-Hidalgo L; Sobrevilla P
Case Rep Med; 2010; 2010():657579. PubMed ID: 20339522
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
27. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
30. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
31. DNA methyltransferase inhibitors: an updated patent review (2012-2015).
Xu P; Hu G; Luo C; Liang Z
Expert Opin Ther Pat; 2016 Sep; 26(9):1017-30. PubMed ID: 27376512
[TBL] [Abstract][Full Text] [Related]
32. New perspectives of valproic acid in clinical practice.
Činčárová L; Zdráhal Z; Fajkus J
Expert Opin Investig Drugs; 2013 Dec; 22(12):1535-47. PubMed ID: 24160174
[TBL] [Abstract][Full Text] [Related]
33. [Development of HDAC inhibitors].
Sowa Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic regulation and cancer (review).
Chen QW; Zhu XY; Li YY; Meng ZQ
Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
[TBL] [Abstract][Full Text] [Related]
36. Could valproic acid be an effective anticancer agent? The evidence so far.
Brodie SA; Brandes JC
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1097-100. PubMed ID: 25017212
[TBL] [Abstract][Full Text] [Related]
37. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
Terui Y
Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
[TBL] [Abstract][Full Text] [Related]
38. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
[TBL] [Abstract][Full Text] [Related]
39. [Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Kovalëv RA; Stam TA; Ibatulin FM; Bondarev GN; Filatov MV
Vopr Onkol; 2012; 58(6):800-7. PubMed ID: 23600307
[TBL] [Abstract][Full Text] [Related]
40. The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells.
Jafary H; Ahmadian S; Soleimani M
Tumour Biol; 2014 Mar; 35(3):2701-10. PubMed ID: 24213853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]